SDGR Key Statistics, Chart & Performance
The current stock price of SDGR is 13.63 USD. In the past month the price decreased by -26.88%. In the past year, price decreased by -45.15%.
SDGR Technical Analysis
SDGR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SDGR. No worries on liquidiy or solvency for SDGR as it has an excellent financial health rating, but there are worries on the profitability.
SDGR Financial Highlights
Over the last trailing twelve months SDGR reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 0.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.92% | ||
| ROE | -54.77% | ||
| Debt/Equity | 0 |
SDGR Forecast & Estimates
15 analysts have analysed SDGR and the average price target is 25.5 USD. This implies a price increase of 87.09% is expected in the next year compared to the current price of 13.63.
For the next year, analysts expect an EPS growth of 19.01% and a revenue growth 24.67% for SDGR
SDGR Ownership
SDGR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 21.35 | 30.346B | ||
| DOCS | DOXIMITY INC-CLASS A | 15.56 | 5.177B | ||
| WAY | WAYSTAR HOLDING CORP | 14.23 | 4.49B | ||
| HTFL | HEARTFLOW INC | N/A | 2.494B | ||
| CERT | CERTARA INC | 12.61 | 1.142B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 232.4 | 1.088B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.074B | ||
| TDOC | TELADOC HEALTH INC | N/A | 883.203M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 5.28 | 750.14M |
Related stock screener links
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SDGR
Company Profile
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Company Info
SCHRODINGER INC
1540 Broadway, 24th Floor
New York City NEW YORK 10036 US
CEO: Ramy Farid
Employees: 891
Phone: 15032991150
SCHRODINGER INC / SDGR FAQ
What does SCHRODINGER INC do?
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
What is the current price of SDGR stock?
The current stock price of SDGR is 13.63 USD. The price increased by 0.22% in the last trading session.
Does SDGR stock pay dividends?
SDGR does not pay a dividend.
What is the ChartMill rating of SCHRODINGER INC stock?
SDGR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of SDGR stock?
SCHRODINGER INC (SDGR) has a market capitalization of 1.00B USD. This makes SDGR a Small Cap stock.
What is the Short Interest ratio of SCHRODINGER INC (SDGR) stock?
The outstanding short interest for SCHRODINGER INC (SDGR) is 16.84% of its float.